Happy new year 2018

Happy new year 2018 from all the team of Imavita!
We wish to all of you an excellent new year 2018, full of health, projects and preclinical models and preclinical images!

Imavita preclinical CRO and imaging

Categories: News

Innovating imaging of dermatology models

Imavita is proud to announce the acquisition of new Optical Coherence Tomography apparatus.

Since september 2017, Imavita is working on this innovative imaging system (OQ Labscope / Lumedica) which will permit to generate non-invasive, surface tissue quantitative data for pre-clinical models in place at Imavita in Applications of interest, principally in the area of dermatology.OCT preclinical model Imavita

The benefits of this in vivo imaging modality are:

  • Easily and efficiently obtain calibrated quantitative data in preclinical models
  • Deepen understanding of disease mechanisms, disease progression and therapeutic responses
  • Manage costs and capture time course data by avoiding sacrifice of animal models

For more informations, do not hesitate to contact us.

Categories: News

Best wishes for 2017!

Happy new year 2017 from all the team of Imavita!
We wish to all of you an excellent new year 2017, full of health, projects and fantastic images!

Imavita preclinical CRO and imaging

Categories: News

Imavita laboratories have moved

Since January 2nd 2017, Imavita moved its laboratories to Canal Biotech 1, 3 rue des Satellites, 31400 Toulouse, France.

The labs will approximate the team to the in-life / in vivo facilities in which experiments are performed.

Canal Biotech is a public building (Toulouse Metropole / SEMIDIAS)  for company housing dedicated to life sciences.

Categories: News

The team is growing

Imavita is proud to announce the recent recruitment of Elisabeth Bonnard and Jeanne Chapel.

  • Dr Elisabeth Bonnard, Neuropharmacologist, PhD, Project Leader, was graduated on 2004 at the l’Institut de Pharmacologie et de Biologie Structurale, CNRS, Toulouse. She has 10 years of experience as head of pharmacology et PharmaLeads, Paris, France. She brings experience in preclinical development, in vivo models in neurology. Elisabeth will help in the implementation of new preclinical models in the areas of neurology and dermatology.
  • Jeanne Chapel, MSc, Research Scientist, is graduated from University of Paul Sabatier, Toulouse, France (Master Bioingéniérie 2015). Jeanne will work in the in vitro lab and will help in applications of in vivo models for drug efficacy evaluation.

Categories: News

New imaging resources

Imavita is proud to announce the acquisition of new Fluorescence Molecular Tomography imaging apparatus for the evaluation of its models.Imavita Fluoresence Molecular Tomography

Since october 2016, a Fluorescence Tomography system was acquired (FMT2500, Perkin Elmer). The FMT2500 fluorescence tomography imaging system provides the greatest utility of the FMT Systems with the ability to quantitate up to 2 fluorophores simultaneously. It comes with 2 excitation laser channels (680 & 750 nm).

This imaging modality will permit to generate non-invasive, deep tissue quantitative data for pre-clinical models in place at Imavita in Applications of interest.

The benefits of this in vivo imaging modality are:

  • Easily and efficiently obtain calibrated quantitative data in preclinical models
  • Measure and monitor multiple biological processes simultaneously
  • Obtain functional and biological data to improve study designs and enhance decision making
  • Generate 3D, information-rich results
  • Complement the molecular functional findings of fluorescence imaging with other anatomical and/or functional modalities like CT, MRI, PET and
    SPECT
  • Deepen understanding of disease mechanisms, disease progression and therapeutic responses
  • Manage costs and capture time course data by avoiding sacrifice of animal models

For more informations, do not hesitate to contact us.

Categories: News

Research Tax Credit agreement / CIR

Research Tax Credit agreement / CIR

Research Tax Credit agreement / CIR

Imavita has Research Tax Credit agreement / CIR (“Crédit Impôt Recherche“) for years 2016 to 2020 (obtained on April 22th 2016 / download pdf file of Research Tax Credit Accreditation).

This agreement, obtained from the french authorities, permits to the clients working with Imavita to refund R&D spendings to their corporate taxes.

See the following links for more informations on CIR / Research Tax Credit: MESR (Ministère de l’Enseignement Supérieur et de la Recherche)

Summary on Research Tax Credit

All companies incurring R&D expenses are eligible to receive France’s research tax credit, regardless of their size, business sector and nationality.

R&D Imavita

The tax credit covers 30% of all R&D expenses and covers all R&D spending: Salaries, social security contributions, amortization and depreciation allowances, operating costs, subcontracting, patents and monitoring.
The scope of SME spending eligible for the research tax credit has been extended as of 2013 to cover innovation expenses arising from designing prototypes, as well as pilot plants for new products. These expenses are now included in the research tax credit base, at a rate of 20%.
For income tax purposes, the definition of a qualified activity for the Research & Experimentation (R&E) Tax Credit or the research and development (R&D) Tax Credit includes not only the development of new products, but also improvements to products, processes, techniques, formulas, patents, and software applications.

Categories: News

Innovative New Company / JEI status approval

The french authorities approved on September 2013 Imavita as an  Innovative New Company (“Jeune Entreprise Innovante / JEI”) based on its ability and capacity of performing R&D projects.

Categories: News

Gravityscan Badge